NEW YORK (
CHANGE IN RATINGS
Alexandria Real Estate Equities
downgraded to hold at TheStreet Ratings.
upgraded at Goldman from Neutral to Buy, Goldman Sachs said. Company is leveraged to higher debt issuance activity.
rated new Buy at Deutsche. $33 price target. Industry demand should continue to outpace supply.
upgraded at Bernstein to Market Perform from Underperform, Bernstein said. Valuation call, based on a $20 price target.
downgraded at Argus from Buy to Hold, Argus said. Company is facing increased competition in the U.S.
EQT Midstream Partners
rated new Buy at Citigroup. $33 price target. Unique pure play on Marcellus midstream growth that still looks cheap.
upgraded to buy at TheStreet Ratings.
downgraded at Morgan Stanley from Equal-weight to Underweight, Morgan Stanley said. Stock has outperformed its peers, but the company faces margin headwinds. $35 price target.
downgraded at Stifel from Hold to Sell, Stifel Nicolaus said. Pricing will likely collapse with SME merchants.
downgraded at Morgan Stanley from Overweight to Equal-weight, Morgan Stanley said. Company is leveraged to a weaker capital spending environment.
( MHP) rated new Buy at UBS. $64 price target. Prior investments and restructuring provide margin expansion opportunity.
downgraded at Lazard from Buy to Neutral, Lazard said. $65 price target. Company lacks near-term catalysts.
upgraded at Bernstein to Market Perform from Underperform, Bernstein said. Valuation call, based on a $65 price target.
rated new Hold at Keybanc. Margins may already be at peak levels.
rated new Overweight at JP Morgan. $37 price target. Recent asset purchases and sales have led to reinvigorated growth.
upgraded at Lazard to Buy. $31 price target. Gennum deal has attractive synergies and the company is growing in emerging markets.
upgraded at Craig-Hallum from Hold to Buy, Craig-Hallum said. $70 price target. Stock has pulled back, but earnings potential has increased following the Objet merger.
upgraded at UBS to Buy from Neutral, UBS said. $39 price target. Inexpensive given its position in an attractive growth market.
downgraded at Pacific Crest. Estimates also cut, given an expected inventory correction.
STOCK COMMENTS / EPS CHANGES
target raised at Jefferies to $91, Jefferies said. Positive topline data for Abraxane. Buy rating.
target raised at Oppenheimer to $80, Oppenheimer said. Bullish following management meetings. Outperform rating.
cut from Conviction Buy List at Goldman. Valuation call, as the stock is up 41% since June. $11 price target.
estimates, target reduced at BMO. Shares of EXPR now seen reaching $15, according to BMO Capital. Estimates also cut, given the company's new guidance. Outperform rating.
numbers lowered at Jefferies. Shares of HAL now seen reaching $44, Jefferies said. Estimates also lowered on North America weakness. Buy rating.
Helmerich & Payne
numbers lowered at Jefferies.Shares of HP now seen reaching $55, Jefferies said. Estimates also lowered on North American weakness. Buy rating.
numbers raised at Citigroup.Shares of MDVN now seen reaching $70, Citigroup said. Estimates also increased to reflect higher Xtandi US price. Buy rating.
numbers cut at Citigroup. Shares of MOS now seen reaching $69, Citigroup said. Estimates also lowered on disappointing quarterly results. Buy rating.
estimates, target reduced at Credit Suisse. MSCI estimates were cut through 2014, Credit Suisse said. Vanguard loss will cut into profits. Outperform rating and new $31 price target.
estimates trimmed at UBS through 2012 on higher iPhone sales, UBS said. Neutral rating and $35 price target.
estimates, target increased at ThinkEquity. Z estimates were raised through 2013, ThinkEquity said. Strong agent demand will improve pricing power. Buy rating and new $49 price target.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.